Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells

Autor: Abdelfatah Saleh Hassan, H. A., Mitwasi, N., Ullrich, M., Kubeil, M., Toussaint, M., Deuther-Conrad, W., Neuber, C., Arndt, C., Rodrigues Loureiro, L. R., Kegler, A., González Soto, K. E., Belter, B., Rössig, C., Pietzsch, J., Frenz, M., Bachmann, M., Feldmann, A.

Publikováno v: Frontiers in Immunology 14(2023), 1166169

Glioblastoma (GBM) is still an incurable tumor that is associated with high recurrence rate and poor survival despite the current treatment regimes. With the urgent need for novel therapeutic strategies, immunotherapies, especially chimeric antigen r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a7b7e198045e8de2c36b95ca509d5ba
https://doi.org/10.3389/fimmu.2023.1166169

A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells

Autor: Kegler, A., Drewitz, L., Arndt, C., Daglar, C., Rodrigues Loureiro, L. R., Mitwasi, N., Neuber, C., González Soto, K. E., Bartsch, T., Baraban, L., Ziehr, H., Heine, M., Nieter, A., Moreira-Soto, A., Kühne, A., Drexler, J. F., Seliger, B., Laube, M., Máthé, D., Pályi, B., Hajdrik, P., Forgách, L., Kis, Z., Szigeti, K., Bergmann, R., Feldmann, A., Bachmann, M.

Publikováno v: Frontiers in Immunology 14(2023), 1204543

The COVID-19 pandemic caused by SARS-CoV-2 led to millions of infections and deaths worldwide. As this virus evolves rapidly, there is a high need for treatment options, which can win the race against new emerging variants of concern. Here, we descri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4577::fdce3d0afa5c96d96efc48a7e94d2f77
https://www.hzdr.de/publications/Publ-37085-1

A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells.

Autor: Kegler A; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Drewitz L; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Arndt C; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; Mildred Scheel Early Career Center, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Daglar C; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Rodrigues Loureiro L; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Mitwasi N; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Neuber C; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., González Soto KE; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Bartsch T; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Baraban L; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Ziehr H; Department of Pharmaceutical Biotechnology, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Braunschweig, Germany., Heine M; Department of Pharmaceutical Biotechnology, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Braunschweig, Germany., Nieter A; Department of Pharmaceutical Biotechnology, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Braunschweig, Germany., Moreira-Soto A; Institute of Virology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Kühne A; Institute of Virology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Drexler JF; Institute of Virology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Seliger B; Medical Faculty, Martin-Luther-University Halle-Wittenberg, Halle, Germany.; Institute of Translational Immunology, Medical High School, Brandenburg an der Havel, Germany., Laube M; Department of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Máthé D; Department of Biophysics and Radiation Biology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.; Hungarian Centre of Excellence for Molecular Medicine, In Vivo Imaging Advanced Core Facility, Szeged, Hungary.; CROmed Translational Research Ltd., Budapest, Hungary., Pályi B; National Biosafety Laboratory, Division of Microbiological Reference Laboratories, National Public Health Center, Budapest, Hungary., Hajdrik P; Department of Biophysics and Radiation Biology, Faculty of Medicine, Semmelweis University, Budapest, Hungary., Forgách L; Semmelweis University School of Pharmacy, Semmelweis University, Budapest, Hungary., Kis Z; National Biosafety Laboratory, Division of Microbiological Reference Laboratories, National Public Health Center, Budapest, Hungary., Szigeti K; Department of Biophysics and Radiation Biology, Faculty of Medicine, Semmelweis University, Budapest, Hungary., Bergmann R; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; Department of Biophysics and Radiation Biology, Faculty of Medicine, Semmelweis University, Budapest, Hungary., Feldmann A; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; National Center for Tumor Diseases Dresden (NCT), German Cancer Research Center (DKFZ), Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany., Bachmann M; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; National Center for Tumor Diseases Dresden (NCT), German Cancer Research Center (DKFZ), Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Jun 13; Vol. 14, pp. 1204543. Date of Electronic Publication: 2023 Jun 13 (Print Publication: 2023).

Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy.

Autor: Feldmann A; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Hoffmann A; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Bergmann R; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary., Koristka S; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Berndt N; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Arndt C; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Rodrigues Loureiro L; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Kittel-Boselli E; Tumor Immunology, University Cancer Center (UCC), University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Dresden, Germany., Mitwasi N; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Kegler A; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Lamprecht C; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; Department of Neurology, Center of Clinical Neuroscience, University Hospital Carl Gustav Carus Dresden, Dresden, Germany., González Soto KE; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Bachmann M; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; Tumor Immunology, University Cancer Center (UCC), University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, Dresden, Germany.; National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), Dresden, Germany.

Publikováno v: Oncoimmunology [Oncoimmunology] 2020 Jul 03; Vol. 9 (1), pp. 1785608. Date of Electronic Publication: 2020 Jul 03.

CAR-T Cells Immunotherapies for the Treatment of Acute Myeloid Leukemia—Recent Advances.

Autor: Zarychta, Julia¹ (AUTHOR) julia.zarychta99@gmail.com, Kowalczyk, Adrian¹ (AUTHOR) adriankowalczyk31@gmail.com, Krawczyk, Milena¹ (AUTHOR) milenakrawczyk77@gmail.com, Lejman, Monika² (AUTHOR) monika.lejman@umlub.pl, Zawitkowska, Joanna³ (AUTHOR) joanna.zawitkowska@umlub.pl

Publikováno v: Cancers. Jun2023, Vol. 15 Issue 11, p2944. 27p.